Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report

Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with (223)Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangano, Anna Maria, Pacilio, Massimiliano, Ialongo, Pasquale, Semprebene, Alessandro, Ventroni, Guido, Mango, Lucio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872001/
https://www.ncbi.nlm.nih.gov/pubmed/29495541
http://dx.doi.org/10.3390/diagnostics8010018
_version_ 1783309741172195328
author Mangano, Anna Maria
Pacilio, Massimiliano
Ialongo, Pasquale
Semprebene, Alessandro
Ventroni, Guido
Mango, Lucio
author_facet Mangano, Anna Maria
Pacilio, Massimiliano
Ialongo, Pasquale
Semprebene, Alessandro
Ventroni, Guido
Mango, Lucio
author_sort Mangano, Anna Maria
collection PubMed
description Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with (223)Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the (223)Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations.
format Online
Article
Text
id pubmed-5872001
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58720012018-03-29 Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report Mangano, Anna Maria Pacilio, Massimiliano Ialongo, Pasquale Semprebene, Alessandro Ventroni, Guido Mango, Lucio Diagnostics (Basel) Case Report Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with (223)Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the (223)Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations. MDPI 2018-02-27 /pmc/articles/PMC5872001/ /pubmed/29495541 http://dx.doi.org/10.3390/diagnostics8010018 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Mangano, Anna Maria
Pacilio, Massimiliano
Ialongo, Pasquale
Semprebene, Alessandro
Ventroni, Guido
Mango, Lucio
Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
title Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
title_full Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
title_fullStr Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
title_full_unstemmed Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
title_short Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
title_sort dosimetry-based consideration on remission and relapse after therapy with (223)ra-dichloride in castration-resistant prostate cancer (crpc) with bone metastases. a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872001/
https://www.ncbi.nlm.nih.gov/pubmed/29495541
http://dx.doi.org/10.3390/diagnostics8010018
work_keys_str_mv AT manganoannamaria dosimetrybasedconsiderationonremissionandrelapseaftertherapywith223radichlorideincastrationresistantprostatecancercrpcwithbonemetastasesacasereport
AT paciliomassimiliano dosimetrybasedconsiderationonremissionandrelapseaftertherapywith223radichlorideincastrationresistantprostatecancercrpcwithbonemetastasesacasereport
AT ialongopasquale dosimetrybasedconsiderationonremissionandrelapseaftertherapywith223radichlorideincastrationresistantprostatecancercrpcwithbonemetastasesacasereport
AT semprebenealessandro dosimetrybasedconsiderationonremissionandrelapseaftertherapywith223radichlorideincastrationresistantprostatecancercrpcwithbonemetastasesacasereport
AT ventroniguido dosimetrybasedconsiderationonremissionandrelapseaftertherapywith223radichlorideincastrationresistantprostatecancercrpcwithbonemetastasesacasereport
AT mangolucio dosimetrybasedconsiderationonremissionandrelapseaftertherapywith223radichlorideincastrationresistantprostatecancercrpcwithbonemetastasesacasereport

Ejemplares similares